Financial Snapshot

Revenue
$1.582M
TTM
Gross Margin
-133.24%
TTM
Net Earnings
-$14.06M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
26.88%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Book Value
Cash
Q2 2024
P/E
-0.1359
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $16.19M $14.39M $12.84M $15.13M $6.701M $786.0K $15.00K
YoY Change -100.0% 12.51% 12.08% -15.14% 125.73% 752.52% 5140.2%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $0.00 $16.19M $14.39M $12.84M $15.13M $6.701M $786.0K $15.00K
Cost Of Revenue $1.510M $1.628M $1.624M $2.540M $933.9K $63.22K $4.270K
Gross Profit $14.68M $12.76M $11.21M $12.59M $5.767M $722.8K $10.73K
Gross Profit Margin 90.7% 88.68% 87.35% 83.21% 86.06% 91.96% 71.53%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $2.815M $22.90M $21.06M $16.38M $17.22M $8.667M $1.572M $229.8K
YoY Change -87.71% 8.75% 28.58% -4.89% 98.66% 451.37% 584.12%
% of Gross Profit 155.99% 165.06% 146.08% 136.81% 150.29% 217.48% 2141.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $403.6K $1.627M $1.649M $1.722M $1.553M $651.1K $65.90K $0.00
YoY Change -75.19% -1.37% -4.25% 10.92% 138.52% 887.97%
% of Gross Profit 11.08% 12.93% 15.36% 12.34% 11.29% 9.12% 0.0%
Operating Expenses $2.942M $34.47M $22.71M $17.68M $18.77M $9.319M $1.638M $229.8K
YoY Change -91.47% 51.79% 28.4% -5.79% 101.44% 468.94% 612.8%
Operating Profit -$6.376M -$18.28M -$9.949M -$6.473M -$6.186M -$3.551M -$915.1K -$219.1K
YoY Change -65.12% 83.74% 53.71% 4.64% 74.17% 288.11% 317.74%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense -$97.81K $14.19K -$501.2K -$557.0K -$889.9K -$98.01K $28.43K -$178.4K
YoY Change -789.24% -102.83% -10.02% -37.41% 807.97% -444.74% -115.94%
% of Operating Profit
Other Income/Expense, Net -$2.040K -$32.51K $240.00 $10.00 -$16.13K -$153.8K -$27.15K $0.00
YoY Change -93.73% -13647.08% 2300.0% -100.06% -89.51% 466.56%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$6.475M -$18.31M -$10.54M -$5.542M -$6.952M -$3.785M -$916.5K -$397.4K
YoY Change -64.64% 73.71% 90.21% -20.27% 83.67% 312.96% 130.61%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.419M -$18.30M -$10.54M -$5.542M -$6.497M -$3.054M -$57.18K -$380.8K
YoY Change -48.53% 73.59% 90.21% -14.7% 112.76% 5240.57% -84.98%
Net Earnings / Revenue -113.06% -73.28% -43.18% -42.95% -45.57% -7.27% -2538.67%
Basic Earnings Per Share -$8.47 -$0.65 -$0.47
Diluted Earnings Per Share -$8.47 -$19.47 -$467.5K -$501.6K -$838.0K -$463.9K -$7.894K -$52.57K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $221.5K $760.0K $7.119M $2.624M $373.7K $194.3K $127.8K $876.2K
YoY Change -70.85% -89.32% 171.31% 602.17% 92.31% 52.06% -85.42%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $191.5K $560.0K $739.2K $619.7K $945.6K $170.2K $93.04K $2.740K
YoY Change -65.8% -24.24% 19.28% -34.46% 455.69% 82.89% 3295.62%
Inventory
Prepaid Expenses
Receivables $731.1K $2.880M $1.209M $1.514M $1.258M $303.6K $139.0K $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $348.7K $722.6K
Total Short-Term Assets $1.144M $4.210M $9.068M $4.757M $2.578M $668.1K $708.5K $1.602M
YoY Change -72.82% -53.57% 90.6% 84.57% 285.8% -5.7% -55.76%
Property, Plant & Equipment $0.00 $5.210M $7.272M $5.593M $7.411M $3.334M $542.8K $0.00
YoY Change -100.0% -28.35% 30.01% -24.53% 122.32% 514.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $300.0K $430.9K $743.3K $1.219M $773.5K $27.83K $0.00
YoY Change -100.0% -30.37% -42.03% -39.04% 57.64% 2679.3%
Total Long-Term Assets $0.00 $6.870M $18.16M $14.99M $17.84M $10.41M $570.6K $0.00
YoY Change -100.0% -62.17% 21.17% -15.99% 71.43% 1723.75%
Total Assets $1.144M $11.08M $27.23M $19.75M $20.42M $11.07M $1.279M $1.602M
YoY Change
Accounts Payable $584.1K $1.700M $2.520M $1.690M $2.910M $1.260M $60.00K $0.00
YoY Change -65.64% -32.54% 49.11% -41.92% 130.95% 2000.0%
Accrued Expenses $1.370M $1.478M $1.078M $1.025M
YoY Change -7.32% 37.1% 5.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $79.96K $380.0K $25.00K $0.00
YoY Change -100.0% -78.96% 1419.84%
Long-Term Debt Due $70.00K $273.5K $2.546M $1.440M $4.476M $165.8K $0.00
YoY Change -74.41% -89.25% 76.77% -67.83% 2600.48%
Total Short-Term Liabilities $1.897M $3.710M $4.934M $5.950M $6.066M $13.83M $473.8K $51.09K
YoY Change -48.87% -24.81% -17.08% -1.9% -56.15% 2819.08% 827.42%
Long-Term Debt $0.00 $60.00K $134.0K $2.007M $2.176M $401.3K $508.7K $500.0K
YoY Change -100.0% -55.21% -93.33% -7.74% 442.11% -21.1% 1.73%
Other Long-Term Liabilities $2.650M $4.208M $3.975M $4.240M $774.5K $125.2K $0.00
YoY Change -37.03% 5.86% -6.23% 447.42% 518.67%
Total Long-Term Liabilities $0.00 $2.710M $4.342M $5.982M $6.415M $1.176M $633.8K $500.0K
YoY Change -100.0% -37.59% -27.42% -6.74% 445.61% 85.5% 26.77%
Total Liabilities $1.897M $6.430M $9.276M $9.314M $10.40M $13.38M $531.7K $834.5K
YoY Change -70.5% -30.68% -0.41% -10.45% -22.27% 2416.85% -36.29%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 1.112M shares 28.27M shares 22.55M shares
Diluted Shares Outstanding 1.112M shares 942.5K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.9109 Million

About IMAC Holdings, Inc.

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 2 full-time employees. The company went IPO on 2019-02-13. The firm is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The firm is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The firm is also engaged in providing the precision medicine business. The firm's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.

Industry: Services-Specialty Outpatient Facilities, NEC Peers: REGIONAL HEALTH PROPERTIES, INC AlerisLife Inc. BioCorRx Inc. SONIDA SENIOR LIVING, INC. HCA Healthcare, Inc. HQDA ELDERLY LIFE NETWORK CORP. SUNLINK HEALTH SYSTEMS INC